Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Liabilities and Shareholders Equity: 2011-2024

Historic Liabilities and Shareholders Equity for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to $170.5 million.

  • Capricor Therapeutics' Liabilities and Shareholders Equity rose 36.03% to $126.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $584.3 million, marking a year-over-year increase of 144.04%. This contributed to the annual value of $170.5 million for FY2024, which is 190.26% up from last year.
  • Latest data reveals that Capricor Therapeutics reported Liabilities and Shareholders Equity of $170.5 million as of FY2024, which was up 190.26% from $58.7 million recorded in FY2023.
  • Over the past 5 years, Capricor Therapeutics' Liabilities and Shareholders Equity peaked at $170.5 million during FY2024, and registered a low of $34.6 million during FY2020.
  • In the last 3 years, Capricor Therapeutics' Liabilities and Shareholders Equity had a median value of $58.7 million in 2023 and averaged $93.1 million.
  • Data for Capricor Therapeutics' Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 211.50% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Capricor Therapeutics' Liabilities and Shareholders Equity stood at $34.6 million in 2020, then climbed by 19.39% to $41.3 million in 2021, then increased by 21.21% to $50.1 million in 2022, then rose by 17.25% to $58.7 million in 2023, then soared by 190.26% to $170.5 million in 2024.